Summary | Gilead Sciences is limiting enrollment to its patient
assistance program for hepatitis C drugs, which helps people
obtain the Sovaldi and Harvoni treatments when they lack
sufficient insurance coverage or the financial wherewithal to
get the medicines otherwise.
blogs.wsj.com | 16 July 2015